Disease · MONDO_0005065

mesothelioma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. mesothelioma. Diseases, record MONDO_0005065. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005065

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: mesothelioma; Open Targets
Open Targets ID: MONDO_0005065; Open Targets
MeSH: D008654; MeSH
NCI Thesaurus: C3234; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 96 drugs, from EMA Human Drugs; Open Targets

Drugs96

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PEMETREXED	CHEMBL225072	Small molecule	Approval	EMA Human Drugs	28	14	14	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Approval	EMA Human Drugs	8	6	6	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	16	16	16	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 3	TTD	5	4	4	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
RALTITREXED	CHEMBL225071	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
RANPIRNASE	CHEMBL2108479	Enzyme	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
NINTEDANIB	CHEMBL502835	Small molecule	Phase 3	TTD	1	0	0	Drugs and targets
PEGARGIMINASE	CHEMBL3137346	Enzyme	Phase 2/3	TTD	1	0	0	Drugs and targets

1 to 10 of 96

See all 96 drugs

Targets166

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
PDCD1	Programmed cell death protein 1	5	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Approval	https://conductscience.org/library/genes/5133	Drugs and targets
TUBA1A	Tubulin	5	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	5	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	5	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	5	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	5	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	5	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	5	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	5	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/81027	Drugs and targets

1 to 10 of 166

See all 166 targets

Trials85

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02460224	Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.	Phase 1/2	490	2022-02-10	Advanced Solid Tumors	IERAMILIMAB, SPARTALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02903914	Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors	Phase 1	260	2021-09-30	Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma	NUMIDARGISTAT, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03013491	PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas	Phase 1/2	196	2025-06-17	Solid Tumor, Lymphoma	IPILIMUMAB, PACMILIMAB, VEMURAFENIB	Its record names the disease	ClinicalTrials.gov
NCT02341625	A Study of BMS-986148 in Patients With Select Advanced Solid Tumors	Phase 1/2	126	2022-08-18	Advanced Cancer	BMS-986148, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT00738582	An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma	Phase 2	89	2022-09-22	Malignant Pleural Mesothelioma	AMATUXIMAB, CISPLATIN, PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT02899195	Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma	Phase 2	55	2021-04-06	Mesothelioma, Pleural Mesothelioma	CISPLATIN, DURVALUMAB, PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT00509041	Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma	Phase 2	46	2013-01-17	Malignant Mesothelioma	DASATINIB ANHYDROUS	Open Targets' reading of its record	ClinicalTrials.gov
NCT01287520	A Study of LY2090314 in Patients With Advanced or Metastatic Cancer	Phase 1	41	2019-02-25	Advanced Cancer	CARBOPLATIN, LY-2090314, PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT02810418	Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors	Phase 1/2	40	2021-02-02	Neoplasms, Pancreatic Neoplasms	LMB-100, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT03207347	A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)	Phase 2	37	2023-09-15	Mesothelioma, Uveal Melanoma, Renal Cell Carcinoma, Cholangiocarcinoma	NIRAPARIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 85

See all 85 trials

Comparisons in its trials9

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Amatuximab/Pemetrexed/Cisplatin vs Amatuximab: deaths from any cause	4 of 89	0 of 56	145	NCT00738582	Trial comparisons
Amatuximab/Pemetrexed/Cisplatin vs Amatuximab: serious adverse events	38 of 89	15 of 56	145	NCT00738582	Trial comparisons
CX-072 10 mg/kg (Part A and Part A2) vs CX-072 10 mg/kg (Part D): The Percentage of Subjects Experiencing Anti-cancer Activity (ORR) When Given 10 mg/kg CX-072 as Monotherapy	1 of 16	13 of 98	114	NCT03013491	Trial comparisons
Cohort A vs Cohort B: deaths from any cause	23 of 23	14 of 14	37	NCT03207347	Trial comparisons
Cohort A vs Cohort B: serious adverse events	8 of 23	7 of 14	37	NCT03207347	Trial comparisons
Arm A1, Dose Level 1, Phase I Short Infusion 100µg/kg LMB-100 vs Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100: Number of Participants With an Objective Response (OR) (Partial Responses + Complete Responses) in Phase 1 Arm A1	0 of 6	1 of 8	14	NCT02810418	Trial comparisons
140 mcg/kg vs 100 mcg/kg: Number of Participants With Serious and Non-Serious Adverse Events	3 of 4	1 of 1	5	NCT03436732	Trial comparisons
140 mcg/kg LMB-100 + SEL-110 vs 100 mcg/kg LMB-100 + SEL-110: deaths from any cause	2 of 4	1 of 1	5	NCT03436732	Trial comparisons
140 mcg/kg LMB-100 + SEL-110 vs 100 mcg/kg LMB-100 + SEL-110: serious adverse events	3 of 4	1 of 1	5	NCT03436732	Trial comparisons

Papers from its trials45

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34750557	RESULT	1	PubMed
29669604	RESULT	1	PubMed
21220472	RESULT	1	PubMed
20400682	RESULT	1	PubMed
18089874	RESULT	1	PubMed
18006112	RESULT	1	PubMed
16446322	RESULT	1	PubMed
16192580	RESULT	1	PubMed
15084390	RESULT	1	PubMed
12565988	RESULT	1	PubMed

1 to 10 of 45

See all 45 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005065

GET https://conductscience.org/api/diseases/v1/MONDO_0005065/drugs?page=2

API reference For AI assistants